Taysha Gene Therapies (TSHA) Reiterated at Overweight by Cantor Fitzgerald on Phase 1/2 Data

March 25, 2026 7:22 AM

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $19.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found